The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol

Contraception

Volumn 81, Issue 1, 2010, Pages 41-48

  Kroll, Robin ^a   Reape, Kathleen Z ^b   Margolis, Marya ^b  

^a Women's Clinical Research Center   (United States)

^b Duramed Research Inc   (United States)

Author keywords

Extended regimen; Hormone free interval; Low dose; Oral contraception

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL;

ADULT; AGE DISTRIBUTION; ARTICLE; BACKACHE; BILE DUCT DILATATION; CHOLECYSTITIS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HORMONAL CONTRACEPTION; HUMAN; LIFE TABLE; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; NAUSEA; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; PROTEINURIA; RHINOPHARYNGITIS; SELF REPORT; SIDE EFFECT; SINUSITIS; SPOTTING; SYNCOPE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; PREGNANCY; PREGNANCY RATE;

EID: 71149112135     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.07.003     Document Type: Article

References (25)

1. Gerstman B.B., Gross T.P., Kennedy D.L., Bennett R.C., Tomita D.K., and Stadel B.V. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health 81 (1991) 90-96
2. Speroff L., and DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 81 (1993) 1034-1047
3. Spitzer W.O., Lewis M.A., Heinemann L.A., Thorogood M., and MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312 (1996) 83-88
4. WHO Collaborative Study of Cardiovascular Diseases and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 346 (1995) 1575-1582
5. Gallo M.F., Nanda K., Grimes D.A., and Schulz K.F. Twenty micrograms vs. >20 mcg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 71 (2005) 162-169
6. Fauser B.C.J.M., and van Heusden A. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 18 (1997) 71-106
7. Killick S.R., Fitzgerald C., and Davis A. Ovarian activity in women taking an oral contraceptive containing 20 mcg ethinyl estradiol and 150 mcg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 179 (1998) S18-S24
8. Spona J., Feichtinger W., Kindermann C., Wunsch C., and Brill K. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception 54 (1996) 299-304
9. Schlaff W.D., Lynch A.M., Hughes H.D., Cedars M.I., and Smith D.L. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol 190 (2004) 943-951
10. Endrikat J., Gerlinger C., Plettig K., et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol 17 (2003) 107-114
11. Reape K.Z., DiLiberti C.E., Hendy C.H., and Volpe E.J. Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive. Contraception 77 (2008) 34-39
12. Vandever M.A., Kuehl T.J., Sulak P.J., et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception 77 (2008) 162-170
13. Klipping C., Duijkers I., Trummer D., and Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 78 (2008) 16-25
14. Bachmann G., Sulak P.J., Sampson-Landers C., Benda N., and Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 70 (2004) 191-198
15. Nakajima S.T., Archer D.F., and Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 microg (Loestrin 24 Fe). Contraception 75 (2007) 16-22
16. Archer D.F., Jensen J.T., Johnson J.V., Borisute H., Grubb G.S., and Constantine G.D. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception 74 (2006) 439-445
17. Ortho Tri Cyclen® Lo. Current US Prescribing Information (2004), Ortho-McNeil Pharmaceuticals, Inc., New Jersey
18. FDA Advisory Committee for Reproductive Health Drugs. Final summary minutes. January 23-24, 2007. http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007-4274t1-part1.pdf Accessed March 20, 2009
19. Holt V.L., Scholes D., Wicklund K.G., Cushing-Haugen K.L., and Daling J.R. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 105 (2005) 46-52
20. Holt V.L., Cushing-Haugen K.L., and Daling J.R. Body weight and risk of oral contraceptive failure. Obstet Gynecol 99 (2002) 820-827
21. Brunner L.R., and Hogue C.J. The role of body weight in oral contraceptive failure: results from the 1995 National Survey of Family Growth. Ann Epidemiol 15 (2005) 492-499
22. Brunner Huber L.R., and Toth J.L. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J of Epidemiol 166 (2007) 1306-1311
23. Brunner Huber L.R., Hogue C.J., Stein A.D., Drews C., and Zieman M. Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Ann Epidemiol 16 (2006) 637-643
24. LaGuardia K.D., Shangold G., Fisher A., Friedman A., and Kafrissen M. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. Contraception 67 (2003) 431-437
25. Anderson F.D., Feldman R., and Reape K.Z. Endometrial effects of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception 77 (2008) 91-96